Don't forget the Nov 2017 announcement below. This should create...

Don't forget the Nov 2017 announcement below.
This should create some urgency for those not wanting to miss out  on possible early success. Those thinking they can wait and get on board further down the track might just find out that the train has already left the station!!    
Early Efficacy and Safety Data Read-Out Planned for Alzheimer’s Trial • Interim efficacy and safety data to be available on the first 50 patients completing XanADu, Actinogen’s Phase II trial of Xanamem™ in Alzheimer’s disease, in April-June 2018 • Efficacy and safety data from interim analysis available one year earlier than full study results • Analysis may provide useful early efficacy and safety data on Xanamem in Alzheimer’s disease •